Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
复制标题
DOI：
10.1186/1477-7819-10-170
复制
发表时间：
2012-08-24
影响因子：
3.2
通讯作者：
Ming Z
中科院分区：
文献类型：
--
作者：
Rong B;Yang S;Li W;Zhang W;Ming Z
许多研究调查了恩度联合铂基双重化疗（PBDC）与单独PBDC治疗晚期非小细胞肺癌（NSCLC）的疗效。这项研究是对现有证据的荟萃分析。我们回顾了15项报道恩度联合PBDC与单独PBDC治疗晚期NSCLC的研究。采用固定效应模型或随机效应模型计算合并优势比和95%置信区间的风险比。恩度联合PBDC治疗NSCLC的总有效率（ORR）和疾病控制率（DCR）均显著高于单用PBDC，分别提高14.7%和13.5% （P < 0.00001）。恩度联合PBDC治疗后患者的进展时间（time to progression， TTP）和生活质量（quality of life， QOL）均有改善（P < 0.00001）。本综述中发现的主要不良反应是血液学反应、肝毒性和恶心/呕吐。恩度联合PBDC与单独使用PBDC的不良反应发生率相似（P < 0.05）。与单独使用PBDC相比，恩度联合PBDC具有更高的RR、DCR和TTP，以及更好的生活质量。与单独使用PBDC相比，恩度联合PBDC的不良反应发生率相似。
Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence. Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model. The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05). Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.
登录
查看更多内容
影响因子：
158.5
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
通讯作者：
Johnson, David H.
影响因子：
20.4
作者：
Novello, Silvia;Pimentel, Francisco Luis;Paz-Ares, Luis
通讯作者：
Paz-Ares, Luis
影响因子：
20.4
作者：
Han, Baohui;Xiu, Qingyu;Jin, Xianqiao
通讯作者：
Jin, Xianqiao
DOI：
10.1016/j.bbrc.2007.06.155
发表时间：
2007-09-14
影响因子：
3.1
作者：
Ling, Yun;Yang, Yong;Guo, Qing-Long
通讯作者：
Guo, Qing-Long
影响因子：
5.8
作者：
Kabbinavar, Fairooz F.;Wallace, Joel F.;Hurwitz, Herbert I.
通讯作者：
Hurwitz, Herbert I.